Unraveling Ligand Selectivity in HCAR3: Insights from Cryo-EM Structures

Study Background and Research Question

Hydroxycarboxylic acid receptors (HCARs)—notably HCAR2 (GPR109A/HM74A) and HCAR3 (GPR109B)—are prototypical G-protein coupled receptors (GPCRs) integral to the regulation of lipid metabolism and signaling. Pharmacological modulation of these receptors is of particular interest for treating metabolic disorders such as dyslipidemia. While HCAR2 agonists have demonstrated therapeutic potential, their clinical utility is constrained by adverse effects, including cutaneous flushing. In contrast, the molecular determinants governing HCAR3 ligand binding, selectivity, and downstream signaling remain poorly resolved.

The study by Ye et al. (PLoS Biology, 2025) addresses this knowledge gap by elucidating the structural basis of HCAR3-ligand interactions using cryo-electron microscopy (cryo-EM). This work specifically investigates the recognition and selectivity mechanisms of various agonists—including (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid (Acifran)—across HCAR3 and HCAR2, providing a foundation for rational drug design targeting metabolic disease pathways.

Key Innovation from the Reference Study

The principal innovation of this work lies in the determination of high-resolution cryo-EM structures of HCAR3-Gi protein complexes bound to four distinct agonists: compound 6O, D-phenyllactic acid (PLA), IBC293, and Acifran. Additionally, the structure of the HCAR2-Gi complex with Acifran was solved. These data enable, for the first time, a direct comparison of how these structurally distinct ligands occupy and interact with the orthosteric pockets of HCAR3 and HCAR2.

By integrating structural and functional data, the authors identify key residues—such as F1073.32 (phenylalanine in HCAR3 versus leucine in HCAR2)—that govern ligand selectivity via π–π interactions and differences in pocket geometry. This mechanistic insight is crucial for guiding the design of hypolipidemic agents with improved specificity and fewer side effects, particularly for lipid metabolism research.

Methods and Experimental Design Insights

Ye et al. employed a robust structural biology pipeline to characterize receptor-ligand complexes:

• Protein Expression: HCAR3-Gi and HCAR2-Gi complexes were heterologously expressed in Sf9 insect cells, ensuring protein integrity and post-translational modifications necessary for proper GPCR function.
• Agonist Binding: The receptors were incubated with selective agonists, including Acifran, to form stable complexes suitable for structural determination.
• Cryo-EM Data Collection: High-resolution cryo-EM was used to solve structures at 3.18 Å for Acifran-HCAR3, 3.31 Å for 6O-HCAR3, 3.05 Å for PLA-HCAR3, 3.26 Å for IBC293-HCAR3, and 2.72 Å for Acifran-HCAR2 complexes.
• Functional Assays: Complementary cAMP assays in HEK-293 cells validated the biochemical relevance of observed structural features, confirming ligand-induced receptor activation and G-protein coupling efficiency.

This multi-pronged approach ensures that the structural models are functionally relevant, bridging the gap between atomic-level receptor pharmacology and cellular signaling outcomes.

Core Findings and Why They Matter

The study’s central findings illuminate critical determinants of ligand selectivity in HCAR3:

• Binding Pocket Occupancy: The highest affinity ligand, compound 6O, achieves full occupancy of both R1 and R2 subregions of the HCAR3 orthosteric pocket, a feature absent in lower-affinity ligands.
• Aromatic Interactions: The presence of F1073.32 in HCAR3 enables π–π stacking with aromatic agonists like Acifran, accounting for the receptor’s distinct selectivity profile compared to HCAR2, which possesses leucine at this position.
• Pocket Geometry: Variations in key residues—V/L832.60, Y/N862.63, and S/W9123.48—modulate binding pocket size and shape, further influencing ligand specificity.
• Functional Validation: cAMP assays confirm that these structural determinants translate into measurable differences in agonist potency and efficacy across receptor subtypes, providing a mechanistic basis for the differential pharmacology observed in lipid metabolism regulation (Ye et al., 2025).

Collectively, these insights set the stage for the development of HCAR3-specific hypolipidemic agents, potentially circumventing the adverse effects associated with HCAR2 activation.

Comparison with Existing Internal Articles

Recent internal resources have highlighted Acifran as a selective HM74A/GPR109A and GPR109B agonist central to lipid signaling pathway modulation and metabolic disorder research. For instance, one article underscores Acifran’s role in dissecting receptor-ligand interactions, while another guide details advanced workflow applications in lipid metabolism regulation. These overviews, however, have largely relied on functional and pharmacological characterizations without direct atomic-level evidence.

The reference study extends these perspectives by providing definitive structural validation for Acifran’s binding mode and receptor specificity. Not only does it confirm prior functional observations, but it also enables rationalization of ligand selectivity in mechanistic terms—a major advance over prior resources. For researchers designing metabolic disorder studies or optimizing hypolipidemic agent workflows, these structural insights enhance the interpretability and reproducibility of results, as also discussed in scenario-driven approaches to Acifran use.

Limitations and Transferability

Despite its methodological rigor, several limitations merit consideration:

• The study relies on recombinant protein expression in insect cells, which may not fully capture the receptor microenvironment present in human tissues.
• While cryo-EM provides high-resolution snapshots of receptor-ligand complexes, it does not directly model dynamic conformational changes or post-binding signaling cascades.
• Functional validation was performed in HEK-293 cells, a heterologous system; thus, results should be extrapolated to physiological contexts with caution.
• The findings focus on the structural and pharmacological selectivity between HCAR3 and HCAR2; transferability to other GPCRs or unrelated metabolic pathways remains unproven.

Nonetheless, the detailed atomic models and supporting functional data provide a robust platform for further translational research in lipid metabolism regulation.

Protocol Parameters

• Agonist-receptor complex formation: Incubate purified HCAR3 or HCAR2 with Acifran at saturating concentrations prior to cryo-EM grid preparation.
• Expression system: Use Sf9 insect cells for functional GPCR-Gi complex expression; optimize MOI and harvest time to maximize yield.
• Functional validation: Perform cAMP assays in HEK-293 cells transfected with HCAR3 or HCAR2, treating with Acifran or structurally related agonists to assess signaling efficacy.
• Structure-guided mutagenesis: Target residues F1073.32, V/L832.60, Y/N862.63, and S/W9123.48 to probe their roles in ligand selectivity.
• Sample stability: For Acifran, prepare solutions freshly and store at -20°C, as recommended in product documentation, to preserve compound integrity during structural and functional assays.

Outlook and Implications

These structural revelations bridge a critical gap in our understanding of how selective agonists—such as Acifran—engage HCAR3 versus HCAR2. By mapping the atomic determinants of selectivity, the study empowers rational design of next-generation hypolipidemic agents and facilitates mechanistic research into lipid signaling pathway modulation. The implications extend to improved therapeutic targeting for metabolic disorders and a reduction in off-target side effects linked to non-selective receptor activation.

Research Support Resources

Researchers aiming to replicate or extend these findings may benefit from well-characterized research compounds. Acifran (SKU B6848), a selective HM74A/GPR109A and GPR109B agonist, is widely used for probing lipid metabolism and receptor-ligand interactions in preclinical settings. Its chemical identity as (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid and documented selectivity make it a practical tool for studies of lipid metabolism regulation and signaling, as detailed in both the APExBIO product dossier and recent literature. For workflow optimization, consult structural findings from Ye et al. and internal guides on protocol design and troubleshooting.